TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07371468: A Phase 1, Open-label, Dose-escalation Study (ELEVATE-1) to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a CD19/CD20 T-cell Engager in Participants With B-cell Driven Autoi

Sponsor: GlaxoSmithKline · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 44 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07371468 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07371468 Rescue Dossier →